Last reviewed · How we verify
Placebo (for UFH)
This drug has no known mechanism of action as it is a placebo.
This drug has no known mechanism of action as it is a placebo. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Placebo (for UFH) |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action. It is used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Injection site reaction
Key clinical trials
- Nebulised Heparin in Patients With Severe COVID-19 (PHASE2, PHASE3)
- Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy (PHASE2)
- Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies (PHASE2, PHASE3)
- Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children (PHASE2, PHASE3)
- Protamine Sulfate During Transcatheter Aortic Valve Implantation (PHASE4)
- OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction (PHASE3)
- Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg) (PHASE1)
- Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for UFH) CI brief — competitive landscape report
- Placebo (for UFH) updates RSS · CI watch RSS
- Sanofi portfolio CI